KLK13
Kallikrein-13
Also known as: KLK-L4, KLK13_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UKR3
- Gene
- KLK13
- Ensembl
- ENSG00000167759
- Chromosome
- 19
- Canonical length
- 277 aa
- Protein class
- Cancer-related genes, Enzymes, Predicted secreted proteins
- Secretome location
- Secreted in other tissues
OverviewNCBI Gene
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Expression of this gene is regulated by steroid hormones and may be useful as a marker for breast cancer. [provided by RefSeq, Jan 2017]
Canonical amino-acid sequenceUniProt
277 residues, UniProt reviewed canonical sequence.
>Q9UKR3|KLK13
1 MWPLALVIAS LTLALSGGVS QESSKVLNTN GTSGFLPGGY TCFPHSQPWQ AALLVQGRLL
61 CGGVLVHPKW VLTAAHCLKE GLKVYLGKHA LGRVEAGEQV REVVHSIPHP EYRRSPTHLN
121 HDHDIMLLEL QSPVQLTGYI QTLPLSHNNR LTPGTTCRVS GWGTTTSPQV NYPKTLQCAN
181 IQLRSDEECR QVYPGKITDN MLCAGTKEGG KDSCEGDSGG PLVCNRTLYG IVSWGDFPCG
241 QPDRPGVYTR VSRYVLWIRE TIRKYETQQQ KWLKGPQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against KLK13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 740 nTPM
Expression across tissuesHPA
Tissue
- esophagus: 740 nTPM
- vagina: 187 nTPM
- cervix: 145 nTPM
- salivary gland: 89 nTPM
- tonsil: 60 nTPM
- skin: 16 nTPM
Single-cell type
- esophageal apical cells: 9,819 nCPM
- esophageal suprabasal cells: 717 nCPM
- late spermatids: 418 nCPM
- suprabasal keratinocytes: 170 nCPM
- tuft cells: 104 nCPM
- esophageal basal cells: 62 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 1.8 nTPM
- midbrain: 0.9 nTPM
- hippocampal formation: 0.2 nTPM
- medulla oblongata: 0.2 nTPM
- amygdala: 0.1 nTPM
- basal ganglia: 0.1 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.11
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.38
- DepMap mean gene effect
- 0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads KLK13 as an antibody target. Whether an autoantibody or antibody against KLK13 could matter depends on whether native KLK13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
KLK13 is annotated as secreted, so native KLK13 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label KLK13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...